<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cytokines and inflammation</journal-id><journal-title-group><journal-title xml:lang="en">Cytokines and inflammation</journal-title><trans-title-group xml:lang="ru"><trans-title>Цитокины и воспаление</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1684-7849</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">695474</article-id><article-id pub-id-type="doi">10.17816/CI695474</article-id><article-id pub-id-type="edn">PMGMOC</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Antiviral activity assessment of specific azo compounds against SARS-CoV-2 in <italic>in vitro</italic> experiment</article-title><trans-title-group xml:lang="ru"><trans-title>Оценка противовирусной активности ряда азосоединений в отношении коронавируса SARS-CoV-2 в эксперименте <italic>in vitro</italic></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0999-8212</contrib-id><contrib-id contrib-id-type="spin">5568-8939</contrib-id><name-alternatives><name xml:lang="en"><surname>Litasova</surname><given-names>Elena V.</given-names></name><name xml:lang="ru"><surname>Литасова</surname><given-names>Елена Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>llitasova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4698-6085</contrib-id><contrib-id contrib-id-type="scopus">57000245400</contrib-id><contrib-id contrib-id-type="spin">1857-1769</contrib-id><name-alternatives><name xml:lang="en"><surname>Matyushenko</surname><given-names>Victoria A.</given-names></name><name xml:lang="ru"><surname>Матюшенко</surname><given-names>Виктория Аркадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>matyshenko@iemspb.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9033-0537</contrib-id><contrib-id contrib-id-type="spin">7427-7395</contrib-id><name-alternatives><name xml:lang="en"><surname>Sokolov</surname><given-names>Alexey V.</given-names></name><name xml:lang="ru"><surname>Соколов</surname><given-names>Алексей Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>д-р биол. наук</p></bio><email>biochemsokolov@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6922-7682</contrib-id><contrib-id contrib-id-type="spin">5799-8802</contrib-id><name-alternatives><name xml:lang="en"><surname>Mezhenskaya</surname><given-names>Daria А.</given-names></name><name xml:lang="ru"><surname>Меженская</surname><given-names>Дарья Андреевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>dasmez@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9231-5792</contrib-id><name-alternatives><name xml:lang="en"><surname>Myznikov</surname><given-names>Leonid V.</given-names></name><name xml:lang="ru"><surname>Мызников</surname><given-names>Леонид Витальевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Chemistry), Assistant Professor</p></bio><bio xml:lang="ru"><p>д-р хим. наук, доцент</p></bio><email>myznikov_lv@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7355-5184</contrib-id><contrib-id contrib-id-type="spin">5155-2743</contrib-id><name-alternatives><name xml:lang="en"><surname>Sokolova</surname><given-names>Natalia B.</given-names></name><name xml:lang="ru"><surname>Соколова</surname><given-names>Наталья Борисовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Chemistry), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. хим. наук, доцент</p></bio><email>nsokolova@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4636-0565</contrib-id><contrib-id contrib-id-type="spin">6289-7281</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbunov</surname><given-names>Nikolay P.</given-names></name><name xml:lang="ru"><surname>Горбунов</surname><given-names>Николай Петрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>niko_laygo@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0548-3745</contrib-id><contrib-id contrib-id-type="spin">5562-1057</contrib-id><name-alternatives><name xml:lang="en"><surname>Berson</surname><given-names>Yulia M.</given-names></name><name xml:lang="ru"><surname>Берсон</surname><given-names>Юлия Михайловна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>juletschka.ber@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5552-9874</contrib-id><contrib-id contrib-id-type="spin">9282-9259</contrib-id><name-alternatives><name xml:lang="en"><surname>Rak</surname><given-names>Alexandra Y.</given-names></name><name xml:lang="ru"><surname>Рак</surname><given-names>Александра Яковлевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology)</p></bio><bio xml:lang="ru"><p>канд. биол. наук</p></bio><email>alexandrak.bio@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2801-1508</contrib-id><contrib-id contrib-id-type="spin">3469-3600</contrib-id><name-alternatives><name xml:lang="en"><surname>Isakova-Sivak</surname><given-names>Irina N.</given-names></name><name xml:lang="ru"><surname>Исакова-Сивак</surname><given-names>Ирина Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biology), Corresponding Member of the Russian Academy of Sciences</p></bio><bio xml:lang="ru"><p>д-р биол. наук, чл.-кор. РАН</p></bio><email>isakova.sivak@iemspb.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Experimental Medicine</institution></aff><aff><institution xml:lang="ru">Институт экспериментальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute for Experimental Medicine</institution></aff><aff><institution xml:lang="ru">Институт экспериментальной медицины</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-12-16" publication-format="electronic"><day>16</day><month>12</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-12-25" publication-format="electronic"><day>25</day><month>12</month><year>2025</year></pub-date><volume>22</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>128</fpage><lpage>137</lpage><history><date date-type="received" iso-8601-date="2025-10-29"><day>29</day><month>10</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-11-30"><day>30</day><month>11</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Litasova E.V., Matyushenko V.A., Sokolov A.V., Mezhenskaya D.А., Myznikov L.V., Sokolova N.B., Gorbunov N.P., Berson Y.M., Rak A.Y., Isakova-Sivak I.N.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Литасова Е.В., Матюшенко В.А., Соколов А.В., Меженская Д.А., Мызников Л.В., Соколова Н.Б., Горбунов Н.П., Берсон Ю.М., Рак А.Я., Исакова-Сивак И.Н.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Litasova E.V., Matyushenko V.A., Sokolov A.V., Mezhenskaya D.А., Myznikov L.V., Sokolova N.B., Gorbunov N.P., Berson Y.M., Rak A.Y., Isakova-Sivak I.N.</copyright-holder><copyright-holder xml:lang="ru">Литасова Е.В., Матюшенко В.А., Соколов А.В., Меженская Д.А., Мызников Л.В., Соколова Н.Б., Горбунов Н.П., Берсон Ю.М., Рак А.Я., Исакова-Сивак И.Н.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-12-25"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://cijournal.ru/1684-7849/article/view/695474">https://cijournal.ru/1684-7849/article/view/695474</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND: </bold>Transferrin receptor 1 (TfR1, CD71) is a multifunctional protein important for maintaining cellular iron homeostasis by binding to the main iron transporter transferrin (Tf). In addition to Tf, it can bind and transfer proteins, viruses, chemotherapeutic agents, and other biomolecules to the cell. Ferristatin II, a TfR1 degradation inducer, has previously been shown to inhibit SARS-CoV-2 infection in Vero cells; however, this agent cannot be used as a medicinal product, because its metabolism produces carcinogenic benzidine derivatives.</p> <p><bold>AIM: </bold>To assess the antiviral activity of specific azo compounds (structural analogs of ferristatin II) to identify common structural patterns of compounds that are the most effective against SARS-CoV-2. The findings will be used to develop safer antiviral analogs of ferristatin II.</p> <p><bold>METHODS: </bold>The paper investigates the antiviral activity of 15 compounds, including 5 <italic>de novo</italic> compounds generated by organic synthesis. The antiviral activity of the drugs was evaluated by their ability to inhibit the replication of SARS-CoV-2 Delta in Vero cell culture. Cytotoxicity of the compounds for this cell line was determined by the MTS assay. Additionally, the ability of the most effective compounds to inhibit iron uptake by Vero cells was assessed using the HMRhoNox-M chemosensor.</p> <p><bold>RESULTS: </bold>In the studied stains similar to ferristatin II, direct black (average inhibitory concentration IC<sub>50</sub> = 53.7 μM), direct green (IC<sub>50</sub> = 53.6 μM), direct diazo black C (IC<sub>50</sub> = 28.2 μM), and direct black 2K (IC<sub>50</sub> = 45.3 μM) inhibited the viral activity. In addition, direct green showed pronounced toxicity to Vero cells (CC<sub>50</sub> = 29.1 μM); whereas none of the black dyes showed cytotoxicity at a highest concentration of 200 μM. The recorded decrease in viral replication in the presence of the drugs correlated with the reduced ability of Vero cells to capture iron, indicating the involvement of TfR1 in the antiviral activity of direct azo stains.</p> <p><bold>CONCLUSION: </bold>The study identified general patterns of direct azo dyes that are most active against SARS-CoV-2, i.e. approximately four acidic groups (sulfo groups) at the ends of the molecule and a small rigid flat linker (benzidine) connecting them. The findings open up prospects for the development of safe analogs of ferristatin II. In particular, benzidine may be replaced with less toxic tetramethylbenzidine and diaminoanthraquinone to reduce carcinogenic activity; to improve the structure, we propose to replace the sulfo groups with carboxyl groups.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование. </bold>Трансферриновый рецептор 1 (TfR1, CD71) является мультифункциональным белком, играющим важную роль в поддержании клеточного гомеостаза железа за счёт связывания с основным переносчиком железа — трансферрином (Tf). Помимо Tf, он способен связывать и переносить в клетку различные белки, вирусы, химиотерапевтические препараты и другие биомолекулы. Ранее был продемонстрирован эффект ингибирования инфекции SARS-CoV-2 при обработке клеток Vero ферристатином II — индуктором деградации TfR1; однако данный препарат не может быть использован как лекарственное средство ввиду образования канцерогенных производных бензидина при его метаболизме.</p> <p><bold>Цель исследования. </bold>Оценить противовирусную активность ряда азосоединений — структурных аналогов ферристатина II — с целью выявления общих структурных закономерностей соединений, демонстрирующих наибольшую эффективность против SARS-CoV-2. Полученные результаты будут использованы для разработки более безопасных аналогов ферристатина II, обладающих противовирусными свойствами.</p> <p><bold>Методы. </bold>В работе изучена противовирусная активность 15 соединений, 5 из которых были получены <italic>de novo </italic>методами органического синтеза. Противовирусную оценку препаратов проводили по их способности ингибировать репродукцию коронавируса SARS-CoV-2 линии Delta на культуре клеток Vero. Цитотоксичность соединений для данной клеточной линии определяли в МТТ тесте. Дополнительно для наиболее эффективных соединений была проведена оценка способности ингибировать захват железа клетками Vero с использованием хемосенсора HMRhoNox-M.</p> <p><bold>Результаты. </bold>Среди изученных красителей — аналогов ферристатина II — вирус-ингибирующей активностью обладали соединения прямой чёрный (среднеингибиторная концентрация IC<sub>50</sub> = 53,7 мкМ), прямой зелёный (IC<sub>50</sub> = 53,6 мкМ), прямой диазочёрный С (IC<sub>50</sub> = 28,2 мкМ) и прямой чёрный 2К (IC<sub>50</sub> = 45,3 мкМ). При этом соединение прямой зелёный проявляло выраженную токсичность для клеток Vero (CC<sub>50</sub> = 29,1 мкМ), тогда как ни один из чёрных красителей не демонстрировал цитотоксичности при максимальной концентрации 200 мкМ. Данные о снижении репродукции вируса в присутствии препаратов коррелировали со снижением способности клеток Vero захватывать железо, что указывает на вовлечённость TfR1 в противовирусную активность прямых азокрасителей.</p> <p><bold>Заключение. </bold>Определены общие закономерности прямых азокрасителей, наиболее активных в отношении SARS-CoV-2: присутствие на концах молекулы порядка четырёх кислотных групп (сульфогруппы) и небольшого жёсткого плоского линкера (бензидина), соединяющего их. Полученные данные открывают перспективы для разработки безопасных аналогов ферристатина II; в частности, для минимизации канцерогенных свойств бензидин может быть заменён на менее токсичные тетраметилбензидин и диаминоантрахинон, а для оптимизации структуры предлагается заменить сульфогруппы на карбоксильные.</p></trans-abstract><kwd-group xml:lang="en"><kwd>transferrin receptor 1</kwd><kwd>inflammation</kwd><kwd>antiviral drug</kwd><kwd>organic synthesis</kwd><kwd>SARS-CoV-2</kwd><kwd>iron transport</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>трансферриновый рецептор 1</kwd><kwd>воспаление</kwd><kwd>противовирусный препарат</kwd><kwd>органический синтез</kwd><kwd>SARS-CoV-2</kwd><kwd>транспорт железа</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="ru">Министерство науки и высшего образования Российской Федерации</institution></institution-wrap><institution-wrap><institution xml:lang="en">Ministry of Science and Higher Education of the Russian Federation</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Pahwa R, Goyal A, Jialal I. Chronic inflammation. [Updated 2023 Aug 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Chavda VP, Feehan J, Apostolopoulos V. Inflammation: The Cause of All Diseases. Cells. 2024;13(22):1906. doi: 10.3390/cells13221906 EDN: DNKUYB</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Guo Q, Qian C, Wang X, Qian ZM. Transferrin receptors. Exp Mol Med. 2025;57(4):724–732. doi: 10.1038/s12276-025-01436-x EDN: TZCTVI</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Aisen P. Transferrin receptor 1. Int J Biochem Cell Biol. 2004;36(11):2137–2143. doi: 10.1016/j.biocel.2004.02.007</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Alim T, Yang B, Zhang Y, et al. Elevated transferrin receptor 1 promoting B-cell autoimmunity in systemic lupus erythematosus. Int Immunopharmacol. 2025;158:114804. doi: 10.1016/j.intimp.2025.114804</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Wang Z, Yin W, Zhu L, et al. Iron drives T helper cell pathogenicity by promoting RNA-binding protein PCBP1-mediated proinflammatory cytokine Production. Immunity. 2018;49(1):80–92.e7. doi: 10.1016/j.immuni.2018.05.008</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Aba Ü, Maslak İC, İpşir C, et al. A novel homozygous germline mutation in transferrin receptor 1 (TfR1) leads to combined immunodeficiency and provides new insights into iron-immunity axis. J Clin Immunol. 2024;44(2):55. doi: 10.1007/s10875-024-01658-0 EDN: AQLFUF</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Li L, Xia Y, Yuan S, et al. Iron deprivation restrains the differentiation and pathogenicity of T helper 17 cell. J Leukoc Biol. 2021;110(6):1057–1067. doi: 10.1002/JLB.3MA0821-015R EDN: MWKMPZ</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Wang W, Ma Z, Feng X, et al. TfR1 mediated iron metabolism dysfunction as a potential therapeutic target for osteoarthritis. Arthritis Res Ther. 2024;26(1):71. doi: 10.1186/s13075-024-03304-x EDN: LYSIKK</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Wessling-Resnick M. Crossing the iron gate: why and how transferrin Receptors Mediate Viral Entry. Annu Rev Nutr. 2018;38:431–458. doi: 10.1146/annurev-nutr-082117-051749</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Mazel-Sanchez B, Niu C, Williams N, et al. Influenza A virus exploits transferrin receptor recycling to enter host cells. Proc Natl Acad Sci U S A. 2023;120(21):e2214936120. doi: 10.1073/pnas.2214936120 EDN: FVLWVW</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Liao Z, Wang C, Tang X, et al. Human transferrin receptor can mediate SARS-CoV-2 infection. Proc Natl Acad Sci U S A. 2024;121(10):e2317026121. doi: 10.1073/pnas.2317026121 EDN: CQDNGM</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Sokolov A, Isakova-Sivak I, Grudinina N, et al. Ferristatin II efficiently inhibits SARS-CoV-2 replication in Vero cells. Viruses. 2022;14(2):317. doi: 10.3390/v14020317 EDN: ODCJTD</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Xiao Y, Wang L, Fang SS, et al. Direct blue 53, a biological dye, inhibits SARS-CoV-2 infection by blocking ACE2 and spike interaction in vitro and in vivo. Virology. 2023;586:105–114. doi: 10.1016/j.virol.2023.07.006 EDN: FZFAPX</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Borenfreund E, Babich H, Martin-Alguacil N. Comparisons of two in vitro cytotoxicity assays-The neutral red (NR) and tetrazolium MTT tests. Toxicol In Vitro. 1988;2(1):1–6. doi: 10.1016/0887-2333(88)90030-6</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Niwa M, Hirayama T, Okuda K, Nagasawa H. A new class of high-contrast Fe(II) selective fluorescent probes based on spirocyclized scaffolds for visualization of intracellular labile iron delivered by transferrin. Org Biomol Chem. 2014;12(34):6590–6597. doi: 10.1039/c4ob00935e EDN: YEKPKB</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Ni S, Yuan Y, Kuang Y, Li X. Iron Metabolism and immune regulation. Front Immunol. 2022;13:816282. doi: 10.3389/fimmu.2022.816282</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Yan M, Chen X, Li X, et al. Transferrin receptor-targeted immunostimulant for photodynamic immunotherapy against metastatic tumors through β-catenin/CREB interruption. Acta Pharm Sin B. 2024;14(9):4118–4133. doi: 10.1016/j.apsb.2024.05.030 EDN: FOJORE</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Neiveyans M, Melhem R, Arnoult C, et al. A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions. MAbs. 2019;11(3):593–605. doi: 10.1080/19420862.2018.1564510</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Pina A, Mastrantuono E, Silva M, et al. Transferrin receptor 1-targeted polymersomes therapy for colorectal cancer. Mater Today Bio. 2025;34:102263. doi: 10.1016/j.mtbio.2025.102263</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Al-Muffti AS, Kiarie IW, Tőzsér J, Mahdi M. Modulation of transferrin receptor by HIV-2. Virol J. 2025;22(1):382. doi: 10.1186/s12985-025-02987-1</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Wang X, Wen Z, Cao H, et al. Transferrin receptor protein 1 Is an Entry factor for rabies virus. J Virol. 2023;97(2):e0161222. doi: 10.1128/jvi.01612-22 EDN: XXJVHZ</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Martínez LE, Daniels-Wells TR, Guo Y, et al. Targeting TfR1 with the ch128.1/IgG1 antibody Inhibits EBV-driven lymphomagenesis in immunosuppressed mice bearing EBV+ human primary B-cells. Mol Cancer Ther. 2021;20(9):1592–1602. doi: 10.1158/1535-7163.MCT-21-0074 EDN: RIMANS</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Haberger V, Elgner F, Roos J, et al. Regulation of the transferrin receptor recycling in hepatitis C virus-replicating cells. Front Cell Dev Biol. 2020;8:44. doi: 10.3389/fcell.2020.00044 EDN: NZTFPL</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Martin DN, Uprichard SL. Identification of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci U S A. 2013;110(26):10777–10782. doi: 10.1073/pnas.1301764110</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Horonchik L, Wessling-Resnick M. The small-molecule iron transport inhibitor ferristatin/NSC306711 promotes degradation of the transferrin receptor. Chem Biol. 2008;15(7):647–653. doi: 10.1016/j.chembiol.2008.05.011</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Byrne SL, Buckett PD, Kim J, et al. Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. PLoS One. 2013;8(7):e70199. doi: 10.1371/journal.pone.0070199</mixed-citation></ref></ref-list></back></article>
